Influenza split vaccine for people aged 60 and older

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized, blinded, controlled Phase I trial enrolls 120 participants aged 60 years and above and randomizes them 1:1:1 into three groups of 40. One group receives an experimental influenza virus split vaccine (0.7 mL), a second group receives a comparator influenza split vaccine, and a third group receives a placebo (phosphate-buffered solution), each given as a single intramuscular injection in the deltoid. Participants have laboratory tests before vaccination and on day 4 after vaccination, and safety and immunogenicity outcomes are monitored through follow-up visits and diary cards. The primary goal is to gather early safety data and signals of immune response in an older adult population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age over 60 years old, gender not limited, and able to provide legal identification;
* Volunteers voluntarily participate in the study and sign an informed consent form;
* Volunteers have the ability to understand research procedures, use thermometers, scales, and fill out diary cards as required, and can participate in all planned follow-up visits.

Exclusion Criteria:

* On the day of enrollment, the axillary temperature was ≥ 37.3 ℃;
* Those who have had influenza in the past 6 months or meet the definition of influenza like cases;
* Have received any influenza vaccine within the past 12 months or have planned to receive any influenza vaccine during the study period;
* Allergies to any components of the research vaccine, history of allergic reactions to the use of gentamicin sulfate, history of severe allergies to any vaccine/drug, or history of asthma;
* Suffering from a serious illness that prevents the completion of the entire study; Within 3 days prior to vaccination, there is an acute illness or an acute exacerbation of a chronic disease;
* Have used antipyretic or analgesic drugs or anti allergic drugs within 3 days before vaccination;
* Have received any vaccine within 2 weeks prior to vaccination;
* Have received immunosuppressive therapy or other immunomodulatory drugs within 6 months prior to receiving the experimental vaccine, For example, immunosuppressive doses of glucocorticoids, monoclonal antibodies, thymosin, interferon, etc., or planned to receive such treatment within one month after the first dose of vaccination to full immunization, but local medication is allowed;
* Suffering from congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, or other autoimmune diseases;
* Suffering from serious chronic diseases, serious cardiovascular diseases, such as hypertension that cannot be controlled by drugs, diabetes that cannot be controlled by drugs or has serious complications, liver and kidney diseases, pulmonary edema, malignant tumors, etc;
* Have received blood or blood related products within the past 6 months;
* Individuals with progressive neurological disorders, including a history of seizures, epilepsy, encephalopathy, Guillain Barr é syndrome, psychiatric or family history;
* Have a history of abnormal coagulation function and have been using anticoagulants within 3 weeks before vaccination;
* Patients with splenectomy, functional splenectomy, splenectomy, or other important organ resection or partial resection;
* Plan to move before the end of the study or leave the local area for a long time during the scheduled study visit;
* Currently or recently planning to participate in other clinical trials;
* Abnormal laboratory test indicators before vaccination;
* Researchers determine any situation that is not suitable for clinical trials.

Where it's running

• Danjiangkou Disease Prevention and Control Center
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Yeqing Tong — Hubei Provincial Center for Disease Control and Prevention
• Study coordinator: Yang Liu
• Email: liuyang30@sinopharm.com
• Phone: 86-010-65777702

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy

  This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.

  Recruiting Phase 2 Asan Medical Center · Seoul · NCT07926217

• Abbott ID NOW at the point of care for flu-like illness in long-term care facilities

  This trial tests whether the Abbott ID NOW rapid test at the point of care in long-term care facilities can help identify influenza sooner for residents 65 and older with fever and respiratory symptoms.

  Recruiting China Medical University Hospital · Taichung · NCT07846423

• Egg-based H5N8 influenza vaccine at multiple doses with or without adjuvant in healthy adults

  This trial tests whether an egg-based H5N8 flu vaccine, given at low to high doses with or without an adjuvant, is safe and can provoke a stronger immune response in healthy adults 18 and older.

  Recruiting at 16 sites Phase 1/2 Sanofi · Tempe, Arizona and 15 other locations · NCT07779408

• Safety and PK of Ingavirin Forte vs Ingavirin in healthy adults under fasting and fed conditions

  This early-phase study tests whether Ingavirin Forte (90 mg + 20 mg) is safe and how it behaves in the body compared with Ingavirin (90 mg) in healthy adults aged 18–45, under different meal conditions.

  Recruiting Phase 1 Valenta Pharm JSC · Saint Petersburg · NCT07645534

• Light-based immune boost to help prevent viral upper respiratory infections

  A daily handheld light therapy device is tested to see if it can lower how often adults at a military medical facility get colds, flu, or other upper respiratory infections.

  Recruiting Mike O'Callaghan Military Hospital · Nellis Air Force Base, Nevada · NCT07610967

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.